2-[Fluorine-18]-fluoro-2-deoxy-d-glucose positron emission tomography/computed tomography versus whole-body diffusion-weighted MRI for detection of malignant lesions: initial experience
Purchase on Springer.com
$39.95 / €34.95 / £29.95 *
* Final gross prices may vary according to local VAT.
The new magnetic resonance whole body diffusion-weighted imaging with background body signal suppression (DWIBS) uses short tau inversion recovery-echo planar imaging sequence under normal respiration. DWIBS is different from 2-[fluorine-18]-fluoro-2-deoxy-d-glucose positron emission tomography (18F-FDG PET) imaging in technology, but their images are similar. We compared the two modalities regarding the detection and characterization of malignant tumors.
DWIBS and 18F-FDG PET/computed tomography (CT) were performed on 16 cancer patients on the same day. The diagnoses were the following: lung cancer (n = 12), colon cancer (n = 2), breast cancer (n = 1), and pulmonary metastasis (n = 1). A total of 27 malignant tumors (15 lung cancer, 5 pulmonary metastases of parathyroid cancer, 3 pulmonary metastases of lung cancer, 3 colon cancer, 1 breast cancer) and seven reference organs around malignant lesions (two liver regions, four normal lymph nodes, one muscle region) were evaluated visually and quantitatively using the apparent diffusion coefficient (ADC) (×10−3 mm2/s) and standardized uptake value (SUV).
Twenty-five (92.6%) of the 27 malignant lesions were detected visually with DWIBS imaging in contrast to 22 malignant tumors (81.5%) with 18F-FDG PET/CT imaging. The quantitative evaluation showed that there was a significant difference between the mean SUVs of the reference organs (n = 7, 1.48 ± 0.62) and the malignant (n = 22, 5.36 ± 2.80) lesions (P < 0.01). However, there was no significant difference between the mean ADCs of the reference organs (n = 7, 1.54 ± 0.24) and the malignant (n = 25, 1.18 ± 0.70) lesions.
DWIBS can be used for the detection of malignant tumors or benign tumors; however, it may be difficult to differentiate between benign and malignant lesions by ADC.
Supplementary Material (0)
- (1994) Staging of mediastinal non-small cell lung cancer with FDG PET, CT, and fusion images: preliminary prospective evaluation. Radiology 191: pp. 371-7
- (2003) Clinical performance of PET/CT in evaluation of cancer: additional value for diagnostic imaging and patient management. J Nucl Med 44: pp. 1200-9
- CrossRef (2003) Non-small cell lung cancer: dual-modality PET/CT in preoperative staging. Radiology 229: pp. 526-3
- CrossRef (2003) Staging of non-small-cell lung cancer with integrated positron-emission tomography and computed tomography. N Engl J Med 348: pp. 2500-7
- (2006) Additional value of PET/CT over PET in assessment of locoregional lymph nodes in thoracic esophageal squamous cell cancer. J Nucl Med 47: pp. 1255-9
- CrossRef (2006) Integrated PET/CT: current applications and future directions. Radiology 238: pp. 405-22
- (2006) 18F-FDG PET/CT in the evaluation of adrenal masses. J Nucl Med 47: pp. 32-7
- (1992) Fast magnetic resonance diffusion-weighted imaging of acute human stroke. Neurology 42: pp. 1717-23
- (1999) Diffusion-weighted single-shot echo planar MR imaging for liver disease. AJR 173: pp. 393-8
- (2003) Current concepts in whole-body imaging using turbo short tau inversion recovery MR imaging. AJR 180: pp. 247-52
- CrossRef (1998) Whole-body turbo STIR MR imaging in unknown primary tumour detection. J Magn Reson Imag 8: pp. 751-3
- CrossRef (2003) Evaluation of liver diffusion isotrophy and characterization of focal hepatic lesions with two single-shot echo-planar MR imaging sequences: prospective study in 66 patients. Radiology 226: pp. 71-8
- (1997) Focal liver masses: characterization with diffusion-weighted echo-planar MR imaging. Radiology 204: pp. 739-44
- (2004) Diffusion weighted whole body imaging with background body signal suppression (DWIBS): technical improvement using free breathing, STIR and high resolution 3D display. Rad Med 22: pp. 275-82
- CrossRef (2005) Diffusion-weighted MR imaging of kidneys in healthy volunteers and patients with parenchymal diseases: initial experience. Radiology 235: pp. 911-7
- CrossRef (2002) In vivo measurement of the apparent diffusion coefficient in normal and malignant prostatic tissues using echo-planar imaging. J Magn Reson Imag 16: pp. 196-200
- CrossRef (2004) Diffusion-weighted imaging of prostate cancer. J Comput Assist Tomogr 29: pp. 149-53
- CrossRef (2000) Functional evaluation of hydronephrosis by diffusion-weighted MR imaging: relationship between apparent diffusion coefficient and split glomerular rate. Acta Radiologica 41: pp. 642-6
- CrossRef (2004) Diffusion-weighted single shot planar imaging of colorectal cancer using a sensitivity-encoding technique. Jpn J Clin Oncol 34: pp. 620-6
- CrossRef (2006) Hepatic metastases: diffusion-weighted sensitivity-encoding versus SPIO-enhanced MR imaging. Radiology 239: pp. 122-30
About this Article
- 2-[Fluorine-18]-fluoro-2-deoxy-d-glucose positron emission tomography/computed tomography versus whole-body diffusion-weighted MRI for detection of malignant lesions: initial experience
Annals of Nuclear Medicine
Volume 21, Issue 4 , pp 209-215
- Cover Date
- Print ISSN
- Online ISSN
- Additional Links
- Positron emission tomography/computed tomography
- Diffusion-weighted magnetic resonance imaging
- Industry Sectors
- Author Affiliations